• 1
    Nelson DR, Koymans L, Kamataki T et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 142.
  • 2
    Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 121.
  • 3
    Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991; 4: 168179.
  • 4
    Surbrook SE Jr, Olson MJ. Dominant role of cytochrome P-450 2E1 in human hepatic microsomal oxidation of the CFC-substitute 1,1,1,2-tetrafluoroethane. Drug Metab Dispos 1992; 20: 518524.
  • 5
    Peter R, Bocker R, Beaune PH et al. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 1990; 3: 566573.
  • 6
    Kharasch ED, Thummel KE. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology 1993; 79: 795807.
  • 7
    Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128133.
  • 8
    Niemela O, Parkkila S, Juvonen RO et al. Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. J Hepatol 2000; 33: 893901.
  • 9
    Barnett CR, Petrides L, Wilson J, Flatt PR, Ioannides C. Induction of rat hepatic mixed-function oxidases by acetone and other physiological ketones: their role in diabetes-induced changes in cytochrome P450 proteins. Xenobiotica 1992; 22: 14411450.
  • 10
    Shimojo N, Ishizaki T, Imaoka S et al. Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes. Biochem Pharmacol 1993; 46: 621627.
  • 11
    Song BJ, Veech RL, Saenger P. Cytochrome P450IIE1 is elevated in lymphocytes from poorly controlled insulin-dependent diabetics. J Clin Endocrinol Metab 1990; 71: 10361040.
  • 12
    Lucas D, Farez C, Bardou LG et al. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol 1998; 12: 553558.
  • 13
    Gorski JC, Jones DR, Wrighton SA, Hall SD. Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica 1997; 27: 243256.
  • 14
    Asghar A, Haehner-Daniels BD, Gorski JC, Hall SD. Induction of MDR1 and cytochrome P450 mRNAs by rifampin in human mononuclear cells. Drug Metab Dispos 2002; 30: 2026.
  • 15
    Desiraju RK, Renzi NL Jr, Nayak RK, Ng KT. Pharmacokinetics of chlorzoxazone in humans. J Pharm Sci 1983; 72: 991994.
  • 16
    Ono S, Hatanaka T, Hotta H et al. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 1995; 5: 143150.
  • 17
    Berthou F, Goasduff T, Lucas D et al. Interaction between two probes used for phenotyping cytochromes P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans. Pharmacogenetics 1995; 5: 7279.
  • 18
    Palmer JL, Scott RJ, Gibson A, Dickins M, Pleasance S. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). Br J Clin Pharmacol 2001; 52: 555561.
  • 19
    Zhu B, Ou-Yang DS, Chen XP et al. Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin Pharmacol Ther 2001; 70: 455461.
  • 20
    Thummel KE, Lee CA, Kunze KL, Nelson SD, Slattery JT. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol 1993; 45: 15631569.
  • 21
    Dupont I, Lucas D, Clot P, Menez C, Albano E. Cytochrome P4502E1 inducibility and hydroxyethyl radical formation among alcoholics. J Hepatol 1998; 28: 564571.
  • 22
    Koop DR, Coon MJ. Ethanol oxidation and toxicity: role of alcohol P-450 oxygenase. Alcohol Clin Exp Res 1986; 10 (6 Suppl): 44S49S.
  • 23
    Leclercq IA, Farrell GC, Field J et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 10671075.
  • 24
    Raucy JL, Lasker JM, Kraner JC et al. Induction of cytochrome P450IIE1 in the obese overfed rat. Mol Pharmacol 1991; 39: 275280.
  • 25
    Brouwer KL, Kostenbauder HB, McNamara PJ, Blouin RA. Phenobarbital in the genetically obese Zucker rat. II. In vivo and in vitro assessments of microsomal enzyme induction. J Pharmacol Exp Ther 1984; 231: 654659.
  • 26
    Enriquez A, Leclercq I, Farrell GC, Robertson G. Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats. Biochem Biophys Res Commun 1999; 255: 300306.
  • 27
    Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111: 16451653.
  • 28
    Leclercq I, Horsmans Y, Desager JP, Delzenne N, Geubel AP. Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol 1998; 28: 410416.
  • 29
    Barnett CR, Gibson GG, Wolf CR, Flatt PR, Ioannides C. Induction of cytochrome P450III and P450IV family proteins in streptozotocin-induced diabetes. Biochem J 1990; 268: 765769.
  • 30
    Shimojo N. Cytochrome P450 changes in rats with streptozocin-induced diabetes. Int J Biochem 1994; 26: 12611268.
  • 31
    Song BJ, Veech RL, Park SS, Gelboin HV, Gonzalez FJ. Induction of rat hepatic N-nitrosodimethylamine demethylase by acetone is due to protein stabilization. J Biol Chem 1989; 264: 35683572.
  • 32
    Favreau LV, Malchoff DM, Mole JE, Schenkman JB. Responses to insulin by two forms of rat hepatic microsomal cytochrome P-450 that undergo major (RLM6) and minor (RLM5b) elevations in diabetes. J Biol Chem 1987; 262: 1431914326.
  • 33
    Leclercq I, Horsmans Y, Desager JP, Pauwels S, Geubel AP. Dietary restriction of energy and sugar results in a reduction in human cytochrome P450 2E1 activity. Br J Nutr 1999; 82: 257262.
  • 34
    Woodcroft KJ, Hafner MS, Novak RF. Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology 2002; 35: 263273.
  • 35
    O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994; 56: 359367.
  • 36
    Zhang QY, Dunbar D, Ostrowska A et al. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 1999; 27: 804809.
  • 37
    Raucy JL, Schultz ED, Wester MR et al. Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity. Drug Metab Dispos 1997; 25: 14291435.